The radiation oncology market in the UK is expected to reach a projected revenue of US$ 1,318.2 million by 2033. A compound annual growth rate of 10.6% is expected of the UK radiation oncology market from 2026 to 2033.
Siemens Healthineers AG ADR, Elekta AB ADR, BD, Accuray Inc, IBA RadioPharma Solutions, IsoRay, MeVis Medical Solutions AG, Nordion, Ntp Radioisotopes, Curium Pharma, ViewRay
Other key industry trends
In terms of revenue, UK accounted for 4.2% of the global radiation oncology market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany radiation oncology market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 1,318.2 million by 2033.
As per Macmillan Cancer Support, the proportion of cancer patients in the UK is estimated to be around 47% of the population between 2020 and 2030. The most common form of cancer in the UK is breast cancer. The National Awareness and Early Diagnosis Initiative (NAEDI).
which involved the NHS England, Cancer Research UK, Public Health England, and the Department of Health, promotes early diagnosis of cancer and increased access to proper treatment. This initiative also aims to reduce deaths due to cancer.
The Cancer Research UK and BUPA foundation entered into a partnership to start Cancer Preventive Initiative, which is intended to conduct research on lifestyle and behavioral changes to prevent cancer. The Cancer Reform Strategy mentioned that 40% or less patients in England.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Radiation Oncology Market Outlook will help companies and investors design strategic landscapes.
External Beam Radiation Therapy (Ebrt) was the largest segment with a revenue share of 78.99% in 2025.
Horizon Databook has segmented the U.K. radiation oncology market based on external beam radiation therapy (ebrt), internal beam radiation therapy, systemic targeted radiation therapy covering the revenue growth of each sub-segment from 2021 to 2033.
As per Macmillan Cancer Support, the proportion of cancer patients in the UK is estimated to be around 47% of the population between 2020 and 2030. The most common form of cancer in the UK is breast cancer. The National Awareness and Early Diagnosis Initiative (NAEDI).
which involved the NHS England, Cancer Research UK, Public Health England, and the Department of Health, promotes early diagnosis of cancer and increased access to proper treatment. This initiative also aims to reduce deaths due to cancer.
The Cancer Research UK and BUPA foundation entered into a partnership to start Cancer Preventive Initiative, which is intended to conduct research on lifestyle and behavioral changes to prevent cancer. The Cancer Reform Strategy mentioned that 40% or less patients in England.
U.K. Radiation Oncology Market Treatment Type Outlook (Revenue, USD Million , 2021-2033)
External Beam Radiation Therapy (EBRT)
Internal Beam Radiation Therapy
Systemic Targeted Radiation Therapy
U.K. Radiation Oncology Market Technology Outlook (Revenue, USD Million , 2021-2033)
Image-Guided Radiotherapy (IGRT)
Intensity-Modulated Radiotherapy (IMRT)
Volumetric Modulated Arc Therapy (VMAT)
3D Conformal Radiation Therapy (3D-CRT)
Stereotactic Radiotherapy (SRS / SBRT)
Proton Beam Delivery Technology
Heavy-Ion Delivery Technology
Adaptive Radiotherapy
Upright Beam Delivery Technology
U.K. Radiation Oncology Market Application Outlook (Revenue, USD Million , 2021-2033)
External Beam Radiation Therapy (EBRT)
Internal Beam Radiation Therapy
Radioligand Therapy Applications
U.K. Radiation Oncology Market Target Customer Outlook (Revenue, USD Million , 2021-2033)
Academic & Research Cancer Centers
Government & Public Tertiary Hospitals
Private Oncology Chains
Specialty Proton / Particle Therapy Centers
Nuclear Medicine & Theranostics Centers
Reasons to subscribe to Radiation Oncology Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Radiation Oncology Market Outlook databook
Our clientele includes a mix of Radiation Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Radiation Oncology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Radiation Oncology Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.